Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies, with its lead candidate galinpepimut-S (GPS) targeting WT1-expressing cancers including acute myeloid leukemia (AML) and mesothelioma. The company operates with zero revenue as a pre-commercial entity, burning cash to fund Phase 3 clinical trials while seeking regulatory approval pathways. Stock performance is driven entirely by clinical trial readouts, FDA interactions, partnership announcements, and capital raises rather than traditional business fundamentals.
SELLAS operates the classic biotech development model: raise capital through equity offerings and strategic partnerships, deploy funds into clinical trials to generate safety/efficacy data, seek FDA approval, then commercialize through direct sales or partnerships. The company's value proposition centers on GPS's mechanism as a WT1-targeted cancer vaccine that could address unmet needs in hematologic malignancies where WT1 is overexpressed in 70-80% of AML cases. Monetization depends entirely on successful Phase 3 trial completion, regulatory approval (likely accelerated pathway given orphan drug designations), and either building commercial infrastructure or partnering with larger oncology players for distribution. Current burn rate estimated at $15-20M annually based on clinical trial costs and G&A.
Phase 3 REGAL trial data readouts for GPS in AML maintenance therapy - primary endpoint overall survival data expected in 2026-2027 timeframe
FDA regulatory interactions including breakthrough therapy designation decisions, accelerated approval pathway discussions, and advisory committee outcomes
Partnership or licensing deal announcements with major pharma companies for commercialization rights or ex-US territories
Equity financing announcements and dilution concerns given negative cash flow requiring periodic capital raises
Competitive landscape shifts in AML immunotherapy space including approvals or failures of competing WT1-targeted therapies or CAR-T products
Binary clinical trial risk - Phase 3 REGAL trial failure would likely result in 70-90% equity value destruction with limited pipeline diversification to offset
FDA regulatory pathway uncertainty for cancer vaccines which have historically faced skepticism versus small molecule or antibody therapies, with approval rates below 10% industry-wide for immunotherapy candidates
Reimbursement risk even post-approval as payers increasingly scrutinize oncology drug cost-effectiveness, particularly for maintenance therapies where survival benefits may be measured in months rather than years
Competitive AML treatment landscape evolving rapidly with venetoclax combinations, FLT3 inhibitors, and IDH inhibitors capturing maintenance therapy market share before GPS potential approval
CAR-T and other cellular therapies advancing in AML could render peptide vaccine approaches obsolete if curative outcomes demonstrated
Larger biotechs (e.g., Astellas, Daiichi Sankyo, AbbVie) with approved AML therapies possess commercial infrastructure and payer relationships that SELLAS lacks for future commercialization
Dilution risk from inevitable future equity raises given $0.0B revenue and negative operating cash flow - current $0.5B market cap could face 30-50% dilution in next 12-24 months depending on trial timelines
Going concern risk if trial delays extend cash runway requirements beyond available liquidity, potentially forcing unfavorable partnership terms or asset sales
Warrant overhang and derivative liability exposure from previous financing rounds that could trigger additional dilution if stock price appreciates significantly
low - Clinical trial timelines and FDA regulatory processes operate independently of GDP cycles. However, capital markets access for financing rounds becomes constrained during recessions when risk appetite declines and biotech IPO/follow-on windows close. Patient enrollment can be marginally affected by economic downturns impacting healthcare access, but oncology trials typically maintain enrollment given disease severity.
Rising interest rates create significant headwinds through multiple channels: (1) Higher discount rates compress NPV of future cash flows that are 5-10 years out, disproportionately impacting pre-revenue biotechs, (2) Risk-free rate competition makes speculative biotech equity less attractive versus bonds, (3) Venture capital and biotech-focused funds face higher hurdle rates reducing follow-on financing availability. The 8.28x current ratio provides cushion, but eventual capital raises occur at lower valuations in high-rate environments.
Minimal direct credit exposure given negligible debt (0.01 D/E ratio) and no commercial operations requiring trade credit. However, indirect exposure exists through biotech sector financing conditions - when credit spreads widen and high-yield markets freeze, venture debt and convertible note markets for biotechs also contract, forcing more dilutive equity raises.
momentum/speculative - The 198.4% one-year return and 138.4% three-month return reflect classic biotech momentum trading around binary catalysts. Attracts retail investors seeking lottery-ticket upside, biotech-specialized hedge funds running event-driven strategies around FDA catalysts, and venture investors comfortable with 90% loss probability offset by 10-20x upside scenarios. Not suitable for value or dividend investors given zero cash generation and negative book value economics (9.0x P/B reflects intangible pipeline value only).
high - Clinical-stage biotechs routinely exhibit 50-100% intraday swings on trial data releases. The recent 138% three-month surge indicates active speculation ahead of potential catalysts. Implied volatility likely exceeds 100% annualized, with beta to broader market above 2.0x but low correlation given idiosyncratic clinical/regulatory drivers dominating price action over macro factors.
